Japanese pharma major Daiichi Sankyo (TYO: 4568) has signed an exclusive licensing agreement with US clinical-stage biotech firm Translational Sciences to develop and commercialize the latter’s novel thrombus (blood clot) dissolving agent, TS23, which is currently undergoing Phase I clinical trials.
Based on this agreement, Daiichi Sankyo will pay Translational Sciences unspecified fees, milestones and royalties for exclusive rights to globally develop and commercialize TS23.
This agreement to develop and commercialize this unique thrombus dissolving agent, TS23, is in line with the Daiichi Sankyo R&D strategy to expand its portfolio in the prevention and treatment of thrombosis, the Japanese firm said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze